At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 70 enrolled
Drug / intervention
QR-010 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 1b, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of QR-010 in Subjects With Homozygous ΔF508 Cystic Fibrosis
In Brief
A Phase 2 clinical trial evaluating QR-010 and Placebo for Cystic Fibrosis. Completed, enrolled 70 participants across 27 sites in 10 countries.
Detailed Summary
A randomized, double-blind, placebo-controlled study of single and multiple ascending doses of QR-010 in adults homozygous for ΔF508 Cystic Fibrosis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCystic Fibrosis
CountriesBelgium, Canada, Czechia, Denmark, France, Germany, Italy, Spain, United Kingdom, United States
CollaboratorsEuropean Commission
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartJun 2015
First PostedAug 2015
Primary CompletionSep 2017
TodayJul 2026
First PostedAug 26, 2015
Enrollment StartJun 1, 2015
Primary CompletionSep 14, 2017
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 10.8 years ago
Interventions
QR-010drug
Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton
Placebodrug
Normal Saline